Ligand Pharmaceuticals Incorporated is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.98 USD | -0.49% | -1.17% | +20.39% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.39% | 1.54B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.19% | 238B | |
+7.01% | 204B | |
-6.50% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024